SPOP tips the balance of BETs in cancer

Katie A Fennell¹, Mark A Dawson^{1

2}

Affiliations

¹ Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
² Centre for Cancer Research, University of Melbourne, Melbourne, Australia, and in the Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.

Comment

Katie A Fennell et al. Nat Med. 2017.

. 2017 Sep 8;23(9):1014-1015.

doi: 10.1038/nm.4398.

Katie A Fennell¹, Mark A Dawson^{1

2}

¹ Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
² Centre for Cancer Research, University of Melbourne, Melbourne, Australia, and in the Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.

No abstract available

Comment on

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP. Janouskova H, et al. Nat Med. 2017 Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14. Nat Med. 2017. PMID: 28805821 Free PMC article.
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H. Zhang P, et al. Nat Med. 2017 Sep;23(9):1055-1062. doi: 10.1038/nm.4379. Epub 2017 Aug 14. Nat Med. 2017. PMID: 28805822 Free PMC article.